Brief: Gabather Preliminary Analysis Shows GT-002 Is Safe, Well Tolerated
25/04/2019 14:47
April 25 (Reuters) - Gabather AB GABAT.ST :
* HAS SUCCESSFULLY COMPLETED PHASE 1A STUDY WITH DRUG CANDIDATE GT-002
* NO DRUG-RELATED SIDE EFFECTS HAVE BEEN REPORTED
* PRELIMINARY ANALYSIS SHOWS GT-002 IS SAFE AND WELL TOLERATED
* FINAL STUDY RESULTS TO BE ANNOUNCED IN JUNE 2019
Source text for Eikon: ID:nWkrcgTTBQ
Further company coverage: GABAT.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))